Compare WHG & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | KRRO |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 187.9M |
| IPO Year | 2002 | 2019 |
| Metric | WHG | KRRO |
|---|---|---|
| Price | $19.63 | $10.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | 21.5K | ★ 191.8K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 203.85 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $97,762,000.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $213.56 | ★ N/A |
| Revenue Growth | 3.21 | ★ 181.46 |
| 52 Week Low | $14.70 | $5.20 |
| 52 Week High | $20.97 | $55.89 |
| Indicator | WHG | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 34.70 |
| Support Level | $15.65 | $9.76 |
| Resistance Level | $20.68 | $14.53 |
| Average True Range (ATR) | 0.63 | 0.98 |
| MACD | -0.13 | -0.37 |
| Stochastic Oscillator | 50.34 | 7.37 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.